These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 8782013)
1. HIV biological phenotype: prognosis marker for transmission, disease progression and therapy. Fenyö EM J Biol Regul Homeost Agents; 1995; 9(3):88-90. PubMed ID: 8782013 [No Abstract] [Full Text] [Related]
2. Antiretroviral therapy in human immunodeficiency virus-infected individuals. Spooner KM Adv Intern Med; 1998; 43():373-402. PubMed ID: 9506188 [No Abstract] [Full Text] [Related]
3. Re-emergence of HIV after stopping therapy. Chun TW; Davey RT; Engel D; Lane HC; Fauci AS Nature; 1999 Oct; 401(6756):874-5. PubMed ID: 10553903 [No Abstract] [Full Text] [Related]
4. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758 [TBL] [Abstract][Full Text] [Related]
5. Virological markers of progression: a UK experience. Loveday C J Biol Regul Homeost Agents; 1995; 9(3):100-4. PubMed ID: 8782016 [No Abstract] [Full Text] [Related]
6. Effect of antiretroviral therapy on plasma HIV RNA. Saag MS J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017 [No Abstract] [Full Text] [Related]
7. IL-2 taken to HAART. Gilden D GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116 [TBL] [Abstract][Full Text] [Related]
8. [Combined antiretroviral therapy for prevention of vertical HIV-1 transmission]. Casas E; Gómez-Cano M; Adrados M; García-Lerma G; Calvo F; Soriano V An Med Interna; 1998 Mar; 15(3):148-51. PubMed ID: 9567423 [TBL] [Abstract][Full Text] [Related]
9. [AZT and 3TC treatment in a pregnant woman with HIV infection]. Pardo MJ; Pedrol E; Coll M; Montull S Med Clin (Barc); 1999 Mar; 112(9):358-9. PubMed ID: 10220772 [No Abstract] [Full Text] [Related]
13. Overview on HIV-1-related drug resistance: from theory to clinical practice. Moroni M; Balotta C; Rusconi S J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):15-8. PubMed ID: 9689573 [No Abstract] [Full Text] [Related]
14. [Reactions to the New York "supervirus". A challenge in primary resistance]. Paukstadt W MMW Fortschr Med; 2005 Apr; 147 Spec No 1():86. PubMed ID: 16385890 [No Abstract] [Full Text] [Related]
15. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects]. Marcello A; Giacca M Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891 [No Abstract] [Full Text] [Related]
16. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA). AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161 [TBL] [Abstract][Full Text] [Related]
17. [Resistance to antiretroviral drugs]. Tamalet C; Yahi N; Koch N Med Trop (Mars); 1997; 57(2):121-6. PubMed ID: 9304001 [No Abstract] [Full Text] [Related]
18. Viral resistance: a major challenge in managing HIV disease. Boucher CA; Reedijk M J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014 [No Abstract] [Full Text] [Related]